Safety and Efficacy of Pulsed-Field Ablation With a Pentaspline Ablation Catheter Versus Cryoablation for Atrial Fibrillation: A Systematic Review and Meta-Analysis.

Clin CardiolSep 1, 2026
Clinical ResearchCardiologyOpen access

Yi Cai, Hao Chen, Miao-Fu Li et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the safety and efficacy of pulsed-field ablation (PFA) using a pentaspline catheter versus cryoballoon ablation (CBA) for atrial fibrillation in 2024 patients. The study found no significant difference in atrial tachyarrhythmia recurrence overall, but PFA showed a lower recurrence in paroxysmal AF patients and reduced ablation time compared to CBA.

Key findings

  • No significant difference in atrial tachyarrhythmia recurrence between PFA and CBA (OR = 0.71).
  • PFA showed a lower incidence of AT recurrence in paroxysmal AF (OR = 0.62).
  • PFA resulted in shorter ablation time (MD = -14.12 minutes).
  • Higher hypersensitive troponin release was noted in the PFA group (MD = 547.29).

Why it matters

Understanding the comparative safety and efficacy of PFA and CBA is crucial for clinicians managing atrial fibrillation, as it informs treatment decisions and procedural options for patients.

Source

PubMed · PMID 42669978Free full text on PubMed Central

Published in Clin Cardiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.